Role of islet amyloid in type 2 diabetes mellitus: consequence or cause?
(2002) In Molecular and Cellular Endocrinology 197(1-2). p.205-212- Abstract
- Type 2 diabetes mellitus (DM2) is characterized metabolically by defects in both insulin secretion and insulin action, resulting in hyperglycemia. Histopathologically, DM2 is characterized by depositions of protein in the pancreatic islets. This 'islet amyloid' is present in > 90% of patients with DM2, as well as in monkeys and cats with DM2. The pathogenesis of DM2 is heterogeneous and multifactorial, although insulin resistance seems to be the predominant initiating factor for development of the disease. In the longer term, an insulin secretion defect is also revealed (referred to as 'beta-cell failure'), resulting in clinically manifest diabetes. Recent data, particularly from transgenic mouse studies, indicate that islet amyloidosis... (More)
- Type 2 diabetes mellitus (DM2) is characterized metabolically by defects in both insulin secretion and insulin action, resulting in hyperglycemia. Histopathologically, DM2 is characterized by depositions of protein in the pancreatic islets. This 'islet amyloid' is present in > 90% of patients with DM2, as well as in monkeys and cats with DM2. The pathogenesis of DM2 is heterogeneous and multifactorial, although insulin resistance seems to be the predominant initiating factor for development of the disease. In the longer term, an insulin secretion defect is also revealed (referred to as 'beta-cell failure'), resulting in clinically manifest diabetes. Recent data, particularly from transgenic mouse studies, indicate that islet amyloidosis is a diabetogenic factor, which is both consequence (of insulin resistance) and cause (of beta-cell failure) of DM2. Available transgenic mouse models with islet amyloid formation in vivo will provide the opportunity to assess the effectiveness of novel anti-amyloidogenic therapies, for which promising results are emerging. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/322267
- author
- Hoppener, JWM ; Nieuwenhuis, MG ; Vroom, TM ; Ahrén, Bo LU and Lips, CJM
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- beta-cell failure, factor, diabetogenic, islet amyloid polypeptide, type 2 diabetes, islet amyloid, transgenic mouse models
- in
- Molecular and Cellular Endocrinology
- volume
- 197
- issue
- 1-2
- pages
- 205 - 212
- publisher
- Elsevier
- external identifiers
-
- wos:000179524400026
- pmid:12431814
- scopus:0037195537
- ISSN
- 1872-8057
- DOI
- 10.1016/S0303-7207(02)00266-6
- language
- English
- LU publication?
- yes
- id
- fcfbc48f-35b0-4c4a-9934-37643e0e4df7 (old id 322267)
- date added to LUP
- 2016-04-01 12:12:47
- date last changed
- 2024-01-08 12:24:51
@article{fcfbc48f-35b0-4c4a-9934-37643e0e4df7,
abstract = {{Type 2 diabetes mellitus (DM2) is characterized metabolically by defects in both insulin secretion and insulin action, resulting in hyperglycemia. Histopathologically, DM2 is characterized by depositions of protein in the pancreatic islets. This 'islet amyloid' is present in > 90% of patients with DM2, as well as in monkeys and cats with DM2. The pathogenesis of DM2 is heterogeneous and multifactorial, although insulin resistance seems to be the predominant initiating factor for development of the disease. In the longer term, an insulin secretion defect is also revealed (referred to as 'beta-cell failure'), resulting in clinically manifest diabetes. Recent data, particularly from transgenic mouse studies, indicate that islet amyloidosis is a diabetogenic factor, which is both consequence (of insulin resistance) and cause (of beta-cell failure) of DM2. Available transgenic mouse models with islet amyloid formation in vivo will provide the opportunity to assess the effectiveness of novel anti-amyloidogenic therapies, for which promising results are emerging. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.}},
author = {{Hoppener, JWM and Nieuwenhuis, MG and Vroom, TM and Ahrén, Bo and Lips, CJM}},
issn = {{1872-8057}},
keywords = {{beta-cell failure; factor; diabetogenic; islet amyloid polypeptide; type 2 diabetes; islet amyloid; transgenic mouse models}},
language = {{eng}},
number = {{1-2}},
pages = {{205--212}},
publisher = {{Elsevier}},
series = {{Molecular and Cellular Endocrinology}},
title = {{Role of islet amyloid in type 2 diabetes mellitus: consequence or cause?}},
url = {{http://dx.doi.org/10.1016/S0303-7207(02)00266-6}},
doi = {{10.1016/S0303-7207(02)00266-6}},
volume = {{197}},
year = {{2002}},
}